Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Debt Ratio (2016 - 2025)

Historic Debt Ratio for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 0.55.

  • Northwest Biotherapeutics' Debt Ratio fell 4598.55% to 0.55 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55, marking a year-over-year decrease of 4598.55%. This contributed to the annual value of 0.82 for FY2024, which is 2234.32% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Debt Ratio stood at 0.55, which was down 4598.55% from 0.62 recorded in Q2 2025.
  • Northwest Biotherapeutics' Debt Ratio's 5-year high stood at 12.0 during Q2 2021, with a 5-year trough of 0.55 in Q3 2025.
  • Its 5-year average for Debt Ratio is 3.02, with a median of 1.02 in 2024.
  • Its Debt Ratio has fluctuated over the past 5 years, first soared by 73790.51% in 2021, then plummeted by 8011.64% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Debt Ratio stood at 3.29 in 2021, then decreased by 15.9% to 2.76 in 2022, then tumbled by 61.69% to 1.06 in 2023, then dropped by 22.34% to 0.82 in 2024, then crashed by 33.03% to 0.55 in 2025.
  • Its Debt Ratio stands at 0.55 for Q3 2025, versus 0.62 for Q2 2025 and 0.6 for Q1 2025.